Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 16/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tibenelast SCHEMBL10688452 | 0.98 | STING1 (0.53) | STING1GPR35TSHRHSD17B10BCL2L1 | |
| Tibenelast SCHEMBL635433 | 0.98 | STING1 (0.53) | STING1GPR35TSHRHSD17B10BCL2L1 | |
| SCHEMBL10641965 | 0.94 | STING1 (0.60) | STING1 | |
| SCHEMBL10642176 | 0.94 | STING1 (0.60) | STING1 | |
| SCHEMBL10537567 | 0.93 | STING1 (0.49) | STING1GPR35TSHRHSD17B10ALDH1A1 | |
| SCHEMBL10534791 | 0.93 | STING1 (0.49) | STING1GPR35TSHRHSD17B10ALDH1A1 | |
| SCHEMBL10534655 | 0.92 | STING1 (0.48) | STING1GPR35 | |
| SCHEMBL10646593 | 0.89 | GPR35 (0.61) | STING1GPR35BCL2L1ALDH1A1HPGD | |
| SCHEMBL10535936 | 0.88 | MRGPRX4 (0.51) | STING1GPR35HSD17B10BCL2L1ALDH1A1 | |
| SCHEMBL10688443 | 0.86 | STING1 (0.53) | STING1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 866 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102204898-A | Method for inducing ovulation by using non-polypeptide cyclic adenosine 3',5'-monophosphate (cAMP) level modulator | MERCKSERONO CO LTD | 2011-10-05 | — | — | CN | claimed |
| EP-2176221-B1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | claimed |
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| JP-4532115-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| CN-101778819-A | Indole indane amide compounds and method as the CB2 agonist | BRISTOL MYERS SQUIBB CO | 2010-07-14 | — | — | CN | claimed |
| EP-2176221-A1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | Bristol-Myers Squibb Company (US) | 2010-04-21 | — | — | EP | claimed |
| US-20090298864-A1 | Methods for Treating Mild Cognitive Impairment | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-12-03 | — | — | US | claimed |
| WO-2001019373-A2 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | claimed |
| WO-2001013953-A2 | SYNERGISTIC COMBINATION OF PDE INHIBITORS AND BETA 2 ADRENOCEPTOR AGONIST | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-01 | — | — | WO | claimed |
| CN-1269722-A | Method and composition for modulating responsiveness to corticosteroids | BASF AG (DE) | 2000-10-11 | — | — | CN | claimed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| EP-0998300-A1 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | claimed |
| WO-1998041232-A2 | COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | claimed |
| US-4863923-A | Method of inhibiting superoxide release | ELI LILLY AND COMPANY (US) | 1989-09-05 | — | — | US | claimed |
| EP-0139464-B1 | BENZOTHIOPHENE DERIVATES AS BRONCHODILATORS | ELI LILLY AND COMPANY (US) | 1988-10-19 | — | — | EP | claimed |
| US-4552891-A | BRONCHODILATOR | ELI LILLY AND COMPANY (US) | 1985-11-12 | — | — | US | claimed |
| EP-0139464-A1 | Benzothiophene derivates as bronchodilators | ELI LILLY AND COMPANY (US) | 1985-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298864-A1 | Methods for Treating Mild Cognitive Impairment | CHAT, PSEN2, PSEN1 | STING1 2548/4885GPR35 1024/4885TSHR 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.